Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II randomized double-blind dose-escalation study of intramuscular XJ106-1 for emergency tetanus prophylaxis in healthy Chinese adults
CTR20261550Phase 2Active
- Sponsor
- Xingji Biotechnology
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of XJ106-1, sponsored by Xingji Biotechnology. Started Apr 2026; status: active.
02
Drugs
XJ106-1
Beyond the preview
Go deeper on CTR20261550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261550.